NYSE: RVTYRevvity

    Revvity Q3 2026 Results: Net Income $62.3 Million on Revenue of $729 Million

    • US stocks
    • Earnings
    • Health Care
    A pile of clear glass laboratory measuring cylinders with graduated markings
    chuttersnap chuttersnap, via Wikimedia Commons (CC0). Illustrative image.

    Revvity (NYSE: RVTY) reported results for the third quarter of 2026, the quarter ended 4 Oct 2026, with GAAP revenue of $728.9 million and GAAP net income of $62.3 million; it said on 3 Nov 2026. GAAP diluted EPS from continuing operations was $0.56, and adjusted EPS from continuing operations, a company-defined measure, was $1.38.

    Key highlights

    • Revenue (GAAP): $728.9 million, up 4.3% YoY and down 0.1% QoQ
    • Net income (GAAP): $62.3 million, up 33.5% YoY and 20.2% QoQ
    • Diluted EPS (GAAP, continuing operations): $0.56, up 36.6% YoY
    • Adjusted EPS (company-defined, continuing operations): $1.38, against $1.18 a year earlier
    • Adjusted operating profit margin (company-defined): 28.7%, against 26.1% a year earlier

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ3 2026Q3 2025YoYQ2 2026QoQ
    Revenue728.9698.9+4.3%729.7-0.1%
    95.181.9+16.2%89.3+6.5%
    62.346.7+33.5%51.8+20.2%
    Diluted EPS ($)0.560.41+36.6%0.47+19.1%

    Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 4 Oct 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    The table shows GAAP revenue rising 4.3% from $698.9 million a year earlier and falling 0.1% from $729.7 million in the second quarter of 2026. GAAP operating income rose 16.2% from $81.9 million, and the operating margin was 13.1%, against 11.7% a year earlier.

    Net income (GAAP) rose 33.5% from $46.7 million a year earlier. The company also reports pro forma figures, and its pro forma GAAP EPS from continuing operations was $0.60.

    Adjusted figures exclude amortization and restructuring

    Adjusted operating income, a company-defined measure, was $209.3 million, against $182.4 million a year earlier. The company said it excludes amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related costs, transformation costs, significant litigation matters, and restructuring and other charges, which were $28.4 million in the quarter.

    The company said adjusted EPS from continuing operations was $1.38 in the quarter, against $1.18 a year earlier, and that pro forma adjusted EPS was $1.37.

    Life Sciences grew while Diagnostics revenue fell

    Life Sciences revenue was $379.6 million, up from $342.8 million a year earlier, and the company said its pro forma organic revenue grew 9%. Its adjusted operating profit margin was 31.5%, against 29.5%.

    Diagnostics revenue was $349.3 million, down from $356.1 million, while the company said its pro forma organic revenue grew 5%. Its adjusted operating profit margin was 29.9%, against 25.1% a year earlier.

    Full-year 2026 guidance raised

    The company said it raised its full-year 2026 guidance, on a pro forma basis that excludes China IDX. Its 2026 forecast puts total revenue near $2.86 billion, growth in pro forma organic revenue at about 5%, and pro forma adjusted EPS between $5.40 and $5.45.

    The company has agreed to divest its China IDX immunodiagnostics business, which it said represented about 6% of fiscal 2025 revenue, and expects the sale to close by the end of 2027. CEO Prahlad Singh attributed the quarter's results to broad-based growth and execution, and the company will hold an Investor Day on Friday, 13 Nov 2026.

    Inference

    Diluted weighted average shares were 111.8 million in the quarter, against 115.5 million a year earlier. Purchases of common stock were $102.6 million in the nine months, against $652.5 million a year earlier, and dividends paid in the quarter were $7.8 million.

    The release does not give a dividend per share or the amount of buybacks completed in the quarter. The next dated step it gives is the Investor Day on 13 Nov 2026.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts